A. Felici

发表

The protective side of progesterone

F. Cognetti, G. Ferretti, A. Felici, 2007, Breast Cancer Research.

Aromatase inhibitors in post-menopausal metastatic breast carcinoma

M. Pino, M. Milella, F. Cognetti, 2007, Expert opinion on investigational drugs.

New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinoma

M. Mottolese, S. Di Cosimo, M. Milella, 2005, Cancer.

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

F. Cognetti, A. Fabi, P. Carlini, 2007, Bone.

Ovarian cysts in the postmenopause: is a conservative treatment feasible?

L. Marzetti, M. Veneziano, A. Felici, 1993, Clinical and experimental obstetrics & gynecology.

Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study

F. Cognetti, A. Fabi, G. Arcangeli, 2008, Journal of Neuro-Oncology.

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

S. Cosimo, S. Di Cosimo, M. Milella, 2006, British Journal of Cancer.

Sequential therapy in metastatic clear cell renal carcinoma: TKI–TKI vs TKI–mTOR

G. Tortora, M. Milella, F. Cognetti, 2012, Expert review of anticancer therapy.

Taxanes with anthracyclines as first‐line chemotherapy for metastatic breast carcinoma

F. Cognetti, D. Giannarelli, F. Cuppone, 2005, Cancer.

Dramatic Regression of Multiple Brain Metastases from Breast Cancer with Capecitabine: Another Arrow at the Bow?

F. Cognetti, A. Fabi, P. Carlini, 2006, Cancer investigation.

Pharmacokinetics of Gemcitabine at Fixed-Dose Rate Infusion in Patients with Normal and Impaired Hepatic Function

A. Sacconi, G. Citro, M. Milella, 2009, Clinical pharmacokinetics.

Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.

M. Mandalà, F. Cognetti, A. Fabi, 2007, Thrombosis Research.

Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?

M. Mandalà, F. Cognetti, A. Fabi, 2006, Chest.

Adjuvant chemotherapy in muscle‐invasive bladder carcinoma

M. Gallucci, F. Cognetti, P. Carlini, 2006, Cancer.

Zoledronic Acid and Angiogenesis

F. Cognetti, A. Fabi, S. Tomao, 2007, Clinical Cancer Research.

The other side of p53.

F. Cognetti, G. Ferretti, A. Felici, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate

L. Strigari, P. Marchetti, F. Cognetti, 2017, Anti-cancer drugs.

Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.

F. Cognetti, A. Fabi, P. Carlini, 2008, Anticancer research.

Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit

R. Gralla, F. Cognetti, D. Giannarelli, 2005 .

Forkhead box P3-positive regulatory T cells in immune surveillance and cancer

G. Ferretti, A. Felici, F. Cognettti, 2007, British Journal of Cancer.

Does CTLA4 influence the suppressive effect of CD25+CD4+ regulatory T cells?

M. Pino, F. Cognetti, G. Ferretti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HLA class I residue mismatch and renal graft outcome

C. Casciani, O. Buonomo, A. Felici, 2000, Transplant international : official journal of the European Society for Organ Transplantation.

Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.

M. Picardo, A. Baldi, F. Cognetti, 2013, Future oncology.

Transforming Growth Factor-β Signaling and Regulatory T Cells

M. Mandalà, F. Cognetti, G. Ferretti, 2007 .

Does low-molecular-weight heparin influence cancer-related mortality?

M. Mandalà, F. Cognetti, A. Fabi, 2006, Annals of Oncology.

Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality

F. Cognetti, P. Carlini, D. Giannarelli, 2005 .

Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.

A. Bamias, S. Bracarda, M. Staehler, 2019, Clinical genitourinary cancer.

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.

C. Porta, G. Banna, U. de Giorgi, 2014, Future oncology.

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.

M. Sisani, P. Carlini, S. Bracarda, 2015, Future oncology.

Biology of Metastatic Renal Cell Carcinoma

M. Milella, A. Felici, 2011, Journal of Cancer.

Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.

A. Sacconi, G. Citro, M. Milella, 2009, Clinical pharmacokinetics.

Molecular stool testing for the early detection of colorectal cancer: swan song for p53?

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Darbepoetin alfa and history of thromboembolic events.

F. Cognetti, G. Ferretti, A. Felici, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?

M. Mandalà, F. Cognetti, A. Fabi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial

G. Muto, M. Gallucci, F. Cognetti, 2008 .

Day-surgical Management of Ductal Carcinoma in Situ (Dcis) of the Breast Using Wide Local Excision with Sentinel Node Biopsy

F. Guadagni, G. Simonetti, R. Piccirillo, 2002, Tumori.

Ras oncogene mutations and survival in patients with lung cancer

F. Cognetti, G. Ferretti, A. Felici, 2006, British Journal of Cancer.

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.

G. Muto, M. Gallucci, F. Cognetti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?

C. Porta, A. Russo, M. Silletta, 2015, PloS one.

Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives

M. Milella, M. Santoni, D. Santini, 2013, Expert review of anticancer therapy.

Dosing strategies for anticancer drugs: the good, the bad and body-surface area.

J Verweij, J. Verweij, A. Sparreboom, 2002, European journal of cancer.

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.

M. Mottolese, S. Di Cosimo, F. Cognetti, 2008, Breast.

HER2 and response to paclitaxel in node-positive breast cancer.

F. Cognetti, Francesco Cognetti, Gianluigi Ferretti, 2008, The New England journal of medicine.

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center

Emilio Bria, Antonello Vidiri, Stefano Telera, 2011, Journal of experimental & clinical cancer research : CR.

Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer

M. Mandalà, F. Cognetti, A. Fabi, 2005, Breast Cancer Research and Treatment.

HER2/neu role in breast cancer: from a prognostic foe to a predictive friend

F. Cognetti, A. Fabi, G. Ferretti, 2007, Current opinion in obstetrics & gynecology.

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

S. Barni, C. Porta, V. Adamo, 2015, Journal of Experimental & Clinical Cancer Research.

Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials

S. Di Cosimo, A. Alimonti, F. Cognetti, 2003, Acta oncologica.

Pregnancy Levels of Estrogen and Progesterone: The Double-Edged Sword

F. Cognetti, G. Ferretti, A. Felici, 2007, Cancer Epidemiology Biomarkers & Prevention.

Sentinel Lymphadenectomy in Cutaneous Melanoma

F. Guadagni, S. Chimenti, R. Piccirillo, 2002, Tumori.

A Changing Landscape in Castration-Resistant Prostate Cancer Treatment

M. Pino, P. Carlini, A. Felici, 2012, Front. Endocrin..

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

J. Verweij, W. Loos, J. Verweij, 2006, Cancer Chemotherapy and Pharmacology.

Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey

S. Barni, C. Porta, V. Adamo, 2013, PloS one.

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study

F. Cognetti, L. Moscetti, P. Carlini, 2005, Cancer Chemotherapy and Pharmacology.

Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.

A. Fabi, G. Ferretti, P. Papaldo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

G. Muto, M. Gallucci, F. Cognetti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial.

F. Cognetti, P. Carlini, G. Ferretti, 2007, Journal of the National Cancer Institute.

Re: Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression randomized trial.

F. Cognetti, P. Carlini, G. Ferretti, 2007, Journal of the National Cancer Institute.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients

M. Mottolese, F. Cognetti, A. Fabi, 2006, Cancer Chemotherapy and Pharmacology.

Radioguided-surgery of early breast lesions.

F. Guadagni, R. Piccirillo, E. Cossu, 2001, Anticancer research.

Up‐front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases

M. Rinaldi, G. Tonini, L. Moscetti, 2007, Cancer.

Adverse genetic prognostic profiles define a poor outcome for cystectomy in bladder cancer.

M. Gallucci, R. Merola, S. Sentinelli, 2007, Experimental and molecular pathology.

Taxanes as primary chemotherapy for early breast cancer

M. Milella, F. Cognetti, P. Carlini, 2008, Cancer.

Re: Treatment of human epidermal growth factor receptor 2 overexpressing breast cancer xenografts with multiagent human epidermal growth factor receptor targeted therapy.

F. Cognetti, G. Ferretti, A. Felici, 2007, Journal of the National Cancer Institute.

Self-monitoring versus standard monitoring of oral anticoagulation.

M. Mandalà, F. Cognetti, P. Carlini, 2007, Thrombosis research.

A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.

S. Iacobelli, J. Carles, V. Adamo, 2014 .

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

N. Longo, M. Aglietta, M. Milella, 2010, European urology.

Intracystic carcinoma of the breast. Our experience.

L. Marzetti, A. Felici, M. Piccioni, 1992, European Journal of Gynaecological Oncology.

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

S. Barni, C. Porta, V. Adamo, 2015, Journal of experimental & clinical cancer research : CR.

Preliminary cytogenetic and pharmacogenomic analysis of muscle-invasive transitional-cell carcinoma (TCC) of the bladder in patients (pts) enrolled in the Italian National Research Council (CNR) phase III randomized trial comparing adjuvant cisplatin-gemcitabine (PG) vs observation (OBS) after radic

M. Gallucci, F. Cognetti, F. Boccardo, 2005 .

Transforming growth factor-beta signaling and regulatory T cells.

M. Mandalà, F. Cognetti, G. Ferretti, 2007, Journal of Clinical Oncology.

Minimal Sentinel Node Procedure for Staging Early Breast Cancer

F. Guadagni, G. Simonetti, A. Spila, 2001, Tumori.

Chemotherapy-induced amenorrhea in early breast cancer.

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?

M. Milella, F. Cognetti, A. Fabi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone and lung metastases from intracranial meningioma.

F. Cognetti, A. Fabi, A. Vidiri, 2006, Anticancer research.

Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).

F. Atzori, L. Cerbone, F. Boccardo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biology of Metastatic Renal Cell Carcinoma

M. Milella, A. Felici, 2011, Journal of Cancer.

Is There a Right-Sided Shift for Colorectal Cancer in Women Compared with Men?

L. Kelemen, F. Cognetti, A. Felici, 2006, Cancer Epidemiology Biomarkers & Prevention.

Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.

F. Massari, R. Iacovelli, M. Santoni, 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.

C. Porta, G. Banna, U. de Giorgi, 2014, Future Oncology.